Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with substantial ischemic risk, yet the optimal duration of dual antiplatelet therapy (DAPT) after successful CTO-PCI remains uncertain. We conducted a systematic review and meta-analysis comparing extended DAPT (>12 months) with short...
A. Emara, A. Mansour, Ahmed Wahdan Kasem et al.· Cardiology in Review· 0 citations
Abstract: Transcatheter aortic valve replacement (TAVR) is an established treatment for severe aortic stenosis, with self-expanding valves (SEV) and balloon-expandable valves (BEV) representing the two major platforms. However, their comparative clinical and hemodynamic performance remains uncertain. We systematically...
Ahmed Elazab, A. Ali, Ahmed Elbataa et al.· Cardiology in Review· 0 citations
Cardiovascular disease is an important, well-studied late effect of childhood cancer therapy that may manifest many years after treatment. Radiotherapy, particularly when the heart is exposed, has been associated with multiple cardiovascular complications, including heart failure, coronary artery disease, valvular dise...
Alexandra Khorasanchi, Jenna Farris, Taylor Choi et al.· Cardiology in Review· 0 citations
Social isolation is the objective paucity of social ties; loneliness is the subjective distress of relationships falling short of what one desires. Both are common, affecting roughly a quarter to a third of older adults, and both have cardiovascular consequences through several mechanisms, with some estimates suggestin...
Sharanya Kaushik, Imran Aziz Naeem, S. Nandyal et al.· Cardiology in Review· 0 citations
Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a hu...
Ahmed Talkhan, Amr M. Abou Elezz, N. Borham et al.· Cardiology in Review· 0 citations
BACKGROUND
Pulmonary artery acceleration time (PAAT) is an echocardiographic measure associated with pulmonary artery pressure. Although reduced PAAT has been linked to pulmonary hypertension and adverse outcomes in selected patient populations, less is known about its prognostic significance in community-dwelling olde...
J. A. Nations, Federico E. Mordini, R. Khosla et al.· American Journal of Medicine· 0 citations
Atherosclerotic cardiovascular disease originates in childhood, and cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a major determinant of lifetime cardiovascular risk. Multiple professional societies have published guidelines for lipid screening, diagnosis, and management in pediatric populations...
Nhi D Nguyen, Tzvi Fishkin, A. Makaryus et al.· Cardiology in Review· 0 citations
We used the National Inpatient Sample from 2016 to 2022 to compare complete revascularization with culprit-only percutaneous coronary intervention in adults hospitalized with non-ST-elevation myocardial infarction and multivessel disease. Hospitalizations complicated by cardiogenic shock, cardiac arrest, coronary arter...
M. Elkasaby, A. Alanazi, W. Frishman et al.· Cardiology in Review· 1 citation
In 2025, the US Food and Drug Administration (FDA) removed its prior class-wide boxed warnings for menopausal hormone therapy (MHT), paving the way for increased clinical use. Menopause accelerates cardiovascular risk independently of chronological aging, manifesting as a 7.5% increase in carotid-femoral pulse wave vel...
Ashwin A. Pillai, Aryan Mehta, Shea-Lee Godin et al.· Cardiology in Review· 0 citations
Cardiorenal syndrome (CRS) represents a complex bidirectional interaction between the heart and kidneys whereby acute or chronic failure of one organ precipitates dysfunction in the other. CRS occurring in the setting of cardiogenic shock (CS), or CRS-CS, remains one of the most severe manifestations, contributing subs...
Chirag Mehta, Zola Wilkerson, Sarah A. Bhanushali et al.· Cardiology in Review· 0 citations
Osimertinib, a third-generation EGFR-TKI, is now the standard first-line treatment for EGFR-mutant non-small cell lung cancer and is increasingly given in the adjuvant setting for up to 3 years and in combination with chemotherapy. As exposure has lengthened and shifted toward curative-intent settings, its cardiac effe...
S. Gopu, A. Khader, S. Agrawal et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.